117 related articles for article (PubMed ID: 22488113)
1. Fast and slow versus strong and weak metal-DNA binding: consequences for anti-cancer activity.
Reedijk J
Metallomics; 2012 Jul; 4(7):628-32. PubMed ID: 22488113
[TBL] [Abstract][Full Text] [Related]
2. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
3. A categorization of metal anticancer compounds based on their mode of action.
Gianferrara T; Bratsos I; Alessio E
Dalton Trans; 2009 Oct; (37):7588-98. PubMed ID: 19759927
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium(II)/(III) complexes of 4-hydroxy-pyridine-2,6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro.
Kamatchi TS; Chitrapriya N; Lee H; Fronczek CF; Fronczek FR; Natarajan K
Dalton Trans; 2012 Feb; 41(7):2066-77. PubMed ID: 22183160
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of the ligand based on benzoxazole and its transition metal complexes: DNA-binding and antitumor activity.
Jiang J; Tang X; Dou W; Zhang H; Liu W; Wang C; Zheng J
J Inorg Biochem; 2010 May; 104(5):583-91. PubMed ID: 20202687
[TBL] [Abstract][Full Text] [Related]
6. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure.
Sun RW; Li CK; Ma DL; Yan JJ; Lok CN; Leung CH; Zhu N; Che CM
Chemistry; 2010 Mar; 16(10):3097-113. PubMed ID: 20162647
[TBL] [Abstract][Full Text] [Related]
7. The anticancer activity and HSA binding properties of the structurally related platinum (II) complexes.
Yousefi R; Aghevlian S; Mokhtari F; Samouei H; Rashidi M; Nabavizadeh SM; Tavaf Z; Pouryasin Z; Niazi A; Faghihi R; Papari MM
Appl Biochem Biotechnol; 2012 Jun; 167(4):861-72. PubMed ID: 22622643
[TBL] [Abstract][Full Text] [Related]
8. A structure-based analysis of the vibrational spectra of nitrosyl ligands in transition-metal coordination complexes and clusters.
De La Cruz C; Sheppard N
Spectrochim Acta A Mol Biomol Spectrosc; 2011 Jan; 78(1):7-28. PubMed ID: 21123107
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, crystal structure, studies in solution and cytotoxicity of two new fluorescent platinum(II) compounds containing anthracene derivatives as a carrier ligand.
Marqués-Gallego P; den Dulk H; Brouwer J; Kooijman H; Spek AL; Roubeau O; Teat SJ; Reedijk J
Inorg Chem; 2008 Dec; 47(23):11171-9. PubMed ID: 18975941
[TBL] [Abstract][Full Text] [Related]
10. Studies on the photoactivation of two cytotoxic trans,trans,trans-diazidodiaminodihydroxo-Pt(IV) complexes.
Westendorf AF; Bodtke A; Bednarski PJ
Dalton Trans; 2011 May; 40(19):5342-51. PubMed ID: 21461431
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
12. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
13. Modulation of DNA binding by reversible metal-controlled molecular reorganizations of scorpiand-like ligands.
Inclán M; Albelda MT; Frías JC; Blasco S; Verdejo B; Serena C; Salat-Canela C; Díaz ML; García-España A; García-España E
J Am Chem Soc; 2012 Jun; 134(23):9644-56. PubMed ID: 22594493
[TBL] [Abstract][Full Text] [Related]
14. Platinum-based anticancer agents: innovative design strategies and biological perspectives.
Ho YP; Au-Yeung SC; To KK
Med Res Rev; 2003 Sep; 23(5):633-55. PubMed ID: 12789689
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.
Sava G; Jaouen G; Hillard EA; Bergamo A
Dalton Trans; 2012 Jul; 41(27):8226-34. PubMed ID: 22614531
[TBL] [Abstract][Full Text] [Related]
16. A novel water soluble ligand bridged cobalt(II) coordination polymer of 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (isonicotinic) hydrazone: evaluation of the DNA binding, protein interaction, radical scavenging and anticancer activity.
Raja DS; Bhuvanesh NS; Natarajan K
Dalton Trans; 2012 Apr; 41(15):4365-77. PubMed ID: 22354161
[TBL] [Abstract][Full Text] [Related]
17. Interactions of metal ions with DNA, its constituents and derivatives, which may be relevant for anticancer research.
Turel I; Kljun J
Curr Top Med Chem; 2011; 11(21):2661-87. PubMed ID: 22039873
[TBL] [Abstract][Full Text] [Related]
18. Some uses of transition metal complexes as anti-cancer and anti-HIV agents.
Sun RW; Ma DL; Wong EL; Che CM
Dalton Trans; 2007 Nov; (43):4884-92. PubMed ID: 17992273
[TBL] [Abstract][Full Text] [Related]
19. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.
Reedijk J
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):3611-6. PubMed ID: 12655051
[TBL] [Abstract][Full Text] [Related]
20. Investigation relevant to the conformation of the 17-membered Pt(d(GpG)) macrocyclic ring formed by Pt anticancer drugs with DNA: Pt complexes with a Goldilocks carrier ligand.
Maheshwari V; Marzilli PA; Marzilli LG
Inorg Chem; 2011 Jul; 50(14):6626-36. PubMed ID: 21667929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
